Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FID 123320 ophthalmic solution for ocular redness in pediatric and adult populations
NCT06538662Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of apraclonidine in ocular redness (4 arms), sponsored by Alcon Inc. Primary endpoints: Mean change from baseline in investigator-assessed ocular redness at 15 minutes post-instillation on Day 1 - Adult Cohort, Mean change from baseline in investigator-assessed ocular redness at 10 hours (600 minutes) post-instillation on Day 1 - Adult Cohort and 1 more. Started Oct 2024; status: completed.
02
Drugs
apraclonidine
03
Conditions
ocular redness
Beyond the preview
Go deeper on NCT06538662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06538662.